Tenderwize
Retour à la recherche

Open House Biologika Rabattverträge 2026 - 15 Ranibizumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 30, 2027 · 308 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 15 Ranibizumab

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or volume provided – cannot assess potential revenue.

All eligible competitors can participate; high competition may reduce market share.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Ranibizumab pharmaceutical products under discount contracts.
Afficher le résumé complet

Open-house procedure by Techniker Krankenkasse (TK) and other German health insurers to conclude discount contracts (Rabattverträge) under §130a Abs. 8 SGB V for the active substance Ranibizumab. The contract is non-exclusive, uniform terms, no negotiation, maximum 12-month term starting 01.07.2026. Submission is possible at any time during the contract period, but a monthly cutoff applies for pharmacy software listing. No estimated value provided.

Risques

No estimated value or volume provided – cannot assess potential revenue.

All eligible competitors can participate; high competition may reduce market share.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
  • Must have a valid marketing authorization for the offered Ranibizumab products in Germany/EU/EEA.

Eligibility

  • Must submit a signed self-declaration (Anlage 4) confirming eligibility and reliability.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Biologika Rabattverträge 2026 - 15 Ranibizumab

Conclusion of discount contracts with all eligible pharmaceutical entrepreneurs for the active substance Ranibizumab. No exclusivity, uniform conditions, no individual negotiations.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2026 - Jun 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 30, 2027

Détails de la procédure

Date de publication
18 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
342650-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3